Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)

12 Months Ended

Dec. 31, 2021

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Liabilities at Fair Value

The following table presents the changes in the development derivative liability for the year ended December 31, 2021:

	Fair Value Hierarchy Level	Year ended December 31, 2021
Fair value at inception on February 12, 2021	3	$	—
Non-cash research and development expense		$	16,703
Cash receipts from SFJ		$	3,000
Change in the fair value of development derivative liability		$	8,023
Fair value at end of period	3	$	27,726